Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, … Read more
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) - Total Assets
Latest total assets as of June 2025: €82.42 Billion EUR
Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) holds total assets worth €82.42 Billion EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Total Assets Trend (2013–2024)
This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's total assets of €82.42 Billion consist of 70.7% current assets and 29.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 22.4% |
| Accounts Receivable | €15.73 Billion | 19.3% |
| Inventory | €12.81 Billion | 15.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.20 Billion | 3.9% |
| Goodwill | €830.85 Million | 1.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's current assets represent 70.7% of total assets in 2024, an increase from 59.6% in 2013.
- Cash Position: Cash and equivalents constituted 22.4% of total assets in 2024, up from 15.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 3.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 19.3% of total assets.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors by Total Assets
Key competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950
|
China | CN¥67.71 Billion |
|
Shenzhen Glory Medical Co Ltd
SHE:002551
|
China | CN¥3.56 Billion |
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589
|
China | CN¥15.33 Billion |
|
Hanmi Science
KO:008930
|
Korea | ₩1.45 Trillion |
|
BCM Alliance Bhd
KLSE:0187
|
Malaysia | RM147.86 Million |
|
Qingdao Baheal Medical INC.
SHE:301015
|
China | CN¥7.59 Billion |
|
Excelsior Medical Co Ltd
TW:4104
|
Taiwan | NT$18.80 Billion |
|
CHC Healthcare Group
TW:4164
|
Taiwan | NT$14.83 Billion |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited generates 0.92x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited generates $ 3.47 in net profit.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.54 | 1.52 | 1.64 |
| Quick Ratio | 1.24 | 1.20 | 1.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €20.38 Billion | € 17.69 Billion | € 18.04 Billion |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Advanced Valuation Insights
This section examines the relationship between Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.72 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 3.9% |
| Total Assets | €81.68 Billion |
| Market Capitalization | $1.85 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's assets grew by 3.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2024)
The table below shows the annual total assets of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €81.68 Billion | +3.94% |
| 2023-12-31 | €78.59 Billion | +5.25% |
| 2022-12-31 | €74.67 Billion | +12.93% |
| 2021-12-31 | €66.12 Billion | +10.64% |
| 2020-12-31 | €59.76 Billion | +5.04% |
| 2019-12-31 | €56.89 Billion | +10.51% |
| 2018-12-31 | €51.48 Billion | +81.82% |
| 2017-12-31 | €28.31 Billion | +9.34% |
| 2016-12-31 | €25.90 Billion | +63.18% |
| 2015-12-31 | €15.87 Billion | +11.24% |
| 2014-12-31 | €14.27 Billion | +16.47% |
| 2013-12-31 | €12.25 Billion | -- |